HIIFS
TEVA icon

Harel Insurance Investments & Financial Services’s Teva Pharmaceuticals TEVA Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63B Buy
48,138,805
+2,182,091
+5% +$72.7M 7.93% 1
2026
Q1 		$1.38B Buy
45,956,714
+1,004,941
+2% +$32.3M 9.39% 1
2025
Q4 		$1.4B Buy
44,951,773
+7,255,083
+19% +$179M 12.15% 1
2025
Q3 		$761M Buy
37,696,690
+4,306,363
+13% +$75.6M 6.84% 1
2025
Q2 		$560M Buy
33,390,327
+11,334,780
+51% +$183M 6.4% 2
2025
Q1 		$339M Buy
22,055,547
+22,044,407
+197,885% +$394M 4.44% 5
2024
Q4 		$246K Sell
11,140
-8,558
-43% -$156K ﹤0.01% 200
2024
Q3 		$355K Buy
19,698
+490
+3% +$8.58K 0.01% 187
2024
Q2 		$312K Sell
19,208
-6,543
-25% -$101K 0.01% 215
2024
Q1 		$363K Sell
25,751
-28,507,348
-100% -$359M 0.01% 190
2023
Q4 		$298M Buy
28,533,099
+821,759
+3% +$7.67M 5.24% 3
2023
Q3 		$283M Buy
27,711,340
+27,696,340
+184,642% +$258M 5.58% 2
2023
Q2 		$114K Sell
15,000
-23,283,179
-100% -$189M ﹤0.01% 365
2023
Q1 		$206M Buy
23,298,179
+8,179,950
+54% +$80.9M 4.23% 5
2022
Q4 		$138M Buy
15,118,229
+985,502
+7% +$8.6M 3.03% 8
2022
Q3 		$114M Buy
14,132,727
+2,685,200
+23% +$23.7M 2.79% 7
2022
Q2 		$86.1M Buy
11,447,527
+970,800
+9% +$8.46M 1.81% 18
2022
Q1 		$98.4M Buy
10,476,727
+535,000
+5% +$4.46M 1.61% 21
2021
Q4 		$79.6M Sell
9,941,727
-98,680
-1% -$891K 1.5% 22
2021
Q3 		$97.8M Buy
10,040,407
+100,000
+1% +$936K 2.55% 15
2021
Q2 		$98.6M Sell
9,940,407
-20,000
-0.2% -$212K 2.17% 14
2021
Q1 		$116M Buy
9,960,407
+664,600
+7% +$7.62M 2.18% 13
2020
Q4 		$89.9M Buy
9,295,807
+1,205,229
+15% +$11.5M 2.13% 14
2020
Q3 		$72.9M Buy
8,090,578
+473,526
+6% +$5.01M 2.48% 12
2020
Q2 		$93.9M Buy
7,617,052
+1,087,530
+17% +$12.3M 3.23% 8
2020
Q1 		$58.6M Buy
6,529,522
+1,181,309
+22% +$12.1M 2.75% 11
2019
Q4 		$52.4M Buy
+5,348,213
New +$47.7M 2.28% 14
2019
Q3 		– Sell
-5,348,213
Closed -$49.4M – 569
2019
Q2 		$49.4M Buy
5,348,213
+26,600
+0.5% +$321K 2.64% 10
2019
Q1 		$83.4M Sell
5,321,613
-393,886
-7% -$6.95M 4.86% 4
2018
Q4 		$88.1M Buy
5,715,499
+2,855,802
+100% +$58.5M 5.41% 4
2018
Q3 		$61.6M Buy
2,859,697
+1,063,551
+59% +$24.7M 3.04% 8
2018
Q2 		$43.7M Sell
1,796,146
-286,880
-14% -$5.85M 2.31% 8
2018
Q1 		$35.6M Sell
2,083,026
-996,980
-32% -$19.5M 2.01% 13
2017
Q4 		$45.9M Buy
3,080,006
+540,669
+21% +$8.13M 2.88% 8
2017
Q3 		$44.7M Buy
2,539,337
+1,108,302
+77% +$24.9M 3.67% 5
2017
Q2 		$47.5M Sell
1,431,035
-4,470
-0.3% -$138K 3.84% 5
2017
Q1 		$46.1M Buy
1,435,505
+1,435,151
+405,410% +$49M 4.03% 6
2016
Q4 		$13K Sell
354
-549,806
-100% -$22M ﹤0.01% 288
2016
Q3 		$25.3M Sell
550,160
-671,682
-55% -$35M 3.42% 6
2016
Q2 		$61.4M Buy
+1,221,842
New +$65M 7.35% 2
2016
Q1 		– Sell
-951,507
Closed -$55.8M – 2
2015
Q4 		$62.5M Buy
+951,507
New +$58.8M 7.24% 2

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.63B AUM 45.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return
YDMI
Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Harel Insurance Investments & Financial Services's TEVA Position: Q2 2026 in Review

Harel Insurance Investments & Financial Services increased its Teva Pharmaceuticals (TEVA) stake by 4.7% in Q2 2026, buying an estimated $72.7M and bringing the position to 48,138,805 shares worth $1.63B. The position accounts for 7.93% of the portfolio, ranked #1.

Harel Insurance Investments & Financial Services first reported a position in TEVA in Q4 2015 and has held it in 41 quarters since. 346 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Harel Insurance Investments & Financial Services held 48,138,805 shares of Teva Pharmaceuticals worth $1.63B as of Q2 2026.
  • Harel Insurance Investments & Financial Services bought 2,182,091 Teva Pharmaceuticals shares in Q2 2026, an estimated $72.7M.
  • Teva Pharmaceuticals made up 7.93% of Harel Insurance Investments & Financial Services's portfolio in Q2 2026, its #1 holding.
  • Harel Insurance Investments & Financial Services first reported a position in Teva Pharmaceuticals in Q4 2015 and has held it in 41 quarters since.
  • 346 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2026, filed 29 Jul 2026.